Durable complete remissions in a pivotal phase 2 study of SGN-35 (brentuximab vedotin) in patients with relapsed or refractory hodgkin lymphoma (HL)

Category Systematic review
JournalAnnals of Oncology
Year 2011
This article has no abstract
Epistemonikos ID: 8624b115de37a9a94a7b24c844576ed1233f579f
First added on: Feb 07, 2025